1.36 USD
+0.01 (+0.74%)
1.3 USD
-0.06 (-4.41%)
BIOX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 84 industry peers in the Chemicals industry. BIOX may be in some trouble as it scores bad on both profitability and health. BIOX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year BIOX has reported negative net income.
In the past year BIOX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIOX reported negative net income in multiple years.
In multiple years BIOX reported negative operating cash flow during the last 5 years.
1.2 Ratios
BIOX's Return On Assets of -7.67% is on the low side compared to the rest of the industry. BIOX is outperformed by 76.19% of its industry peers.
With a Return On Equity value of -21.79%, BIOX is not doing good in the industry: 72.62% of the companies in the same industry are doing better.
BIOX has a Return On Invested Capital of 0.61%. This is in the lower half of the industry: BIOX underperforms 76.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.67% | ||
| ROE | -21.79% | ||
| ROIC | 0.61% |
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Operating Margin value of 1.27%, BIOX is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
BIOX has a Gross Margin of 40.62%. This is amongst the best in the industry. BIOX outperforms 84.52% of its industry peers.
In the last couple of years the Gross Margin of BIOX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.27% | ||
| PM (TTM) | N/A | ||
| GM | 40.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
BIOX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIOX has more shares outstanding
BIOX has a worse debt/assets ratio than last year.
2.2 Solvency
The Debt to FCF ratio of BIOX is 5.58, which is a neutral value as it means it would take BIOX, 5.58 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 5.58, BIOX is doing good in the industry, outperforming 77.38% of the companies in the same industry.
BIOX has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
BIOX has a Debt to Equity ratio of 0.26. This is amongst the best in the industry. BIOX outperforms 80.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.58 | ||
| Altman-Z | N/A |
ROIC/WACC0.08
WACC7.25%
2.3 Liquidity
A Current Ratio of 0.94 indicates that BIOX may have some problems paying its short term obligations.
With a Current ratio value of 0.94, BIOX is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
BIOX has a Quick Ratio of 0.94. This is a bad value and indicates that BIOX is not financially healthy enough and could expect problems in meeting its short term obligations.
BIOX has a Quick ratio of 0.65. This is amonst the worse of the industry: BIOX underperforms 89.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.65 |
3. Growth
3.1 Past
BIOX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2230.77%.
Looking at the last year, BIOX shows a very negative growth in Revenue. The Revenue has decreased by -27.90% in the last year.
Measured over the past years, BIOX shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
EPS 1Y (TTM)-2230.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-27.9%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-16.52%
3.2 Future
Based on estimates for the next years, BIOX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.67% on average per year.
BIOX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.87% yearly.
EPS Next Y62.65%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue Next Year-11.13%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
BIOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 5.80, the valuation of BIOX can be described as very cheap.
94.05% of the companies in the same industry are more expensive than BIOX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.03, BIOX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.8 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BIOX is on the same level as its industry peers.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIOX indicates a rather cheap valuation: BIOX is cheaper than 98.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 1.87 | ||
| EV/EBITDA | 12.23 |
4.3 Compensation for Growth
BIOX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BIOX's earnings are expected to grow with 39.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.42%
EPS Next 3Y39.47%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.36
+0.01 (+0.74%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners31.18%
Inst Owner Change-2.52%
Ins Owners0.68%
Ins Owner ChangeN/A
Market Cap86.33M
Revenue(TTM)318.16M
Net Income(TTM)-56.37M
Analysts76
Price TargetN/A
Short Float %2.69%
Short Ratio1.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP-0.13%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-538.65%
Min EPS beat(2)-1015.03%
Max EPS beat(2)-62.27%
EPS beat(4)1
Avg EPS beat(4)-270.05%
Min EPS beat(4)-1015.03%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-295.97%
EPS beat(12)2
Avg EPS beat(12)-113.26%
EPS beat(16)3
Avg EPS beat(16)-102.76%
Revenue beat(2)0
Avg Revenue beat(2)-25.21%
Min Revenue beat(2)-34.42%
Max Revenue beat(2)-16.01%
Revenue beat(4)0
Avg Revenue beat(4)-19.16%
Min Revenue beat(4)-34.42%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-12.83%
Revenue beat(12)2
Avg Revenue beat(12)-9.34%
Revenue beat(16)6
Avg Revenue beat(16)1.35%
PT rev (1m)-23.14%
PT rev (3m)-24.03%
EPS NQ rev (1m)-5.38%
EPS NQ rev (3m)-15.39%
EPS NY rev (1m)-17.33%
EPS NY rev (3m)-243.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.59%
Revenue NY rev (1m)-5.16%
Revenue NY rev (3m)-10.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.8 | ||
| P/S | 0.27 | ||
| P/FCF | 1.87 | ||
| P/OCF | 1.46 | ||
| P/B | 0.33 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.23 |
EPS(TTM)-0.83
EYN/A
EPS(NY)0.23
Fwd EY17.25%
FCF(TTM)0.73
FCFY53.62%
OCF(TTM)0.93
OCFY68.49%
SpS5.01
BVpS4.07
TBVpS-0.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.67% | ||
| ROE | -21.79% | ||
| ROCE | 0.93% | ||
| ROIC | 0.61% | ||
| ROICexc | 0.63% | ||
| ROICexgc | 2.08% | ||
| OM | 1.27% | ||
| PM (TTM) | N/A | ||
| GM | 40.62% | ||
| FCFM | 14.55% |
ROA(3y)-1.49%
ROA(5y)-1.52%
ROE(3y)-4.41%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.17%
GM growth 5Y-3.14%
F-Score4
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.58 | ||
| Debt/EBITDA | 2.49 | ||
| Cap/Depr | 56.55% | ||
| Cap/Sales | 4.04% | ||
| Interest Coverage | 0.22 | ||
| Cash Conversion | 221.17% | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.94 | ||
| Quick Ratio | 0.65 | ||
| Altman-Z | N/A |
F-Score4
WACC7.25%
ROIC/WACC0.08
Cap/Depr(3y)96.4%
Cap/Depr(5y)121.83%
Cap/Sales(3y)4.91%
Cap/Sales(5y)4.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2230.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.33%
EPS Next Y62.65%
EPS Next 2Y51.42%
EPS Next 3Y39.47%
EPS Next 5Y26.67%
Revenue 1Y (TTM)-27.9%
Revenue growth 3Y0.5%
Revenue growth 5Y14.1%
Sales Q2Q%-16.52%
Revenue Next Year-11.13%
Revenue Next 2Y6.62%
Revenue Next 3Y11.13%
Revenue Next 5Y11.87%
EBIT growth 1Y-89.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year120.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.92%
FCF growth 3YN/A
FCF growth 5Y38.53%
OCF growth 1Y18.95%
OCF growth 3YN/A
OCF growth 5Y34.31%
BIOCERES CROP SOLUTIONS CORP / BIOX FAQ
Can you provide the ChartMill fundamental rating for BIOCERES CROP SOLUTIONS CORP?
ChartMill assigns a fundamental rating of 3 / 10 to BIOX.
What is the valuation status for BIOX stock?
ChartMill assigns a valuation rating of 6 / 10 to BIOCERES CROP SOLUTIONS CORP (BIOX). This can be considered as Fairly Valued.
Can you provide the profitability details for BIOCERES CROP SOLUTIONS CORP?
BIOCERES CROP SOLUTIONS CORP (BIOX) has a profitability rating of 2 / 10.
What is the expected EPS growth for BIOCERES CROP SOLUTIONS CORP (BIOX) stock?
The Earnings per Share (EPS) of BIOCERES CROP SOLUTIONS CORP (BIOX) is expected to grow by 62.65% in the next year.